| Chemical Name |
SB-265610 |
| CAS Number |
211096-49-0 |
| MDL Number |
MFCD09971124 |
| Molecular Formula |
C14H9BrN6O |
| Molecular Weight |
357.16 |
Introduction of 211096-49-0 :
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively[1][2]. In Vitro: In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization, IC50 of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner, IC50 of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1[1]. In Vivo: SB-265610 (100 mg/kg/day; oral administration; daily; for 5 days; CXCR2 wild type mice) treatment during the wound repair process markedly delays healing parameters in CXCR2 wild type mice[2].
| Purity |
NLT 98% |
| Storage |
at 20ºC 2 years |
*The above information is for reference only.
